References

cardiovascular

Кардиоваскулярная терапия и профилактика

Cardiovascular Therapy and Prevention

1728-88002619-0125

«SILICEA-POLIGRAF» LLC

cardiovascular-1274

Research Article

ОБЗОРЫ

REVIEWS

Артериальная гипертония и сахарный диабет 2 типа: обладают ли блокаторы рецепторов ангиотензина II особыми преимуществами?

Arterial hypertension and Type 2 diabetes mellitus: any benefits for angiotensin II receptor blockers?

Фомин

В. В.

Fomin

V. V.

Моисеев

С. В.

Moiseev

S. V.

Сагинова

Е. А.

Saginova

E. A.

Московская медицинская академия им. И.М. СеченоваI.M. Sechenov Moscow Medical Academy, Moscow

2007

20062007

63126131

2007

Фомин В.В., Моисеев С.В., Сагинова Е.А.

Fomin V.V., Moiseev S.V., Saginova E.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://cardiovascular.elpub.ru/jour/article/view/1274

Блокаторы рецепторов ангиотензина II – антигипертензивные препараты, имеющие преимущества при лечении артериальной гипертонии (АГ) высокого риска. В статье представлены результаты основных клинических исследований. На примере ирбесартана обосновывается органопротективное действие этого класса препаратов для лечения АГ, ассоциированной с сахарным диабетом 2 типа.

Angiotensin II receptor blockers are antihypertensive medications demonstrating some benefits in the treatment of high-risk arterial hypertension (AH). Principal clinical trials’ results are presented; organo-protective action of this drug class, with irbesartan as an example, is demonstrated for AH and Type 2 diabetes mellitus combination treatment.

артериальная гипертония высокого рискасахарный диабет 2 типаблокаторы рецепторов ангиотензина IIирбесартан

high-risk arterial hypertensionType 2 diabetes mellitusangiotensin II receptor blockersirbesartan

References1

Zanchetti A, Hansson L, Menard J, et al. Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study for the HOT Study Group. J Hypertens 2001; 19: 819-25.

Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood pressure lowering drugs: results of the prospectively designed overviews of randomized trials. Lancet 2000; 356: 1955-64.

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: The Antihypertensive an Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.

ESH-ESC Guidelines Committee. ESH-ESC guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.

Секция артериальной гипертонии ВНОК. Профилактика, диагностика и лечение артериальной гипертензии. Россий- ские рекомендации (второй пересмотр). Москва 2005.

UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Br Med J 1998; 317: 705-13.

Pahor M, Psaty BM, Alderman MH, et al. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000; 23: 888-92.

Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: 1053-9.

Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002; 20: 2099-110.

Wolf G. Molecular mechanisms of angiotensin II in the kidney; emerging role in the progression of renal disease: beyond haemo- dynamics. Nephrol. Dial Transplant 1998; 13: 1131-42.

Dzau VJ. Tissue angiotensin and pathobiology of vascular dis- ease. A unifying hypothesis. Hypertension 2001; 37: 1047-52.

Bottinger EP, Bitzer M. TGF β signaling in renal disease. J Am Soc Nephrol 2002; 13: 2600-10.

Folii F, Saad MJ, Velloso L, et al. Crosstalk between insulin and angiotensin II signaling systems. Exp Clin Endocrinol Diabetes 1999; 107: 133-9.

Cottone S, Vadala A, Mangano MT, et al. Endothelium-derived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives. Am J Hypertens 2000; 13: 172-6.

De Jong PE, Brenner BM. From secondary to primary preven- tion of progressive renal disease: the case for screening for albu- minuria. Kidney Int 2004; 66: 2109-18.

Stehouwer CD. Endothelial dysfunction in diabetic nephropa- thy: state of art and potential significance for non-diabetic renal disease. Nephrol Dial Transplant 2004; 19: 778-81.

Шестакова М.В., Кочемасова Т.В., Горелышева В.А. и др. Роль молекул адгезии (ICAM-1 и Е-селектин) в развитии диабетических микроангиопатий. Тер архив 2002; 6: 24-7.

Шестакова М.В., Ярек-Мартынова И.Р., Иванишина Н.С. и др. Кардиоренальный синдром при сахарном диабете 1 типа: роль дисфункции эндотелия. Кардиология 2005; 6: 35-41.

Rosenson RS, Reasner CA. Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. Curr Opin Cardiol 2004; 19: 480-7. 20. Чазова И.Е., Мычка В.Б. Метаболический синдром. Моск- ва 2004.

Gasic S, Wagner OF, Fasching P, et al. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am J Hypertens 1999;12(2 Pt.1): 217-22.

Pahor M, Franse LV, Deitcher SR, et al. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation 2002; 105: 457-61.

Шестакова М.В. Нефропротекция: роль артериального давления в прогрессировании патологии почек. Зависит ли нефропротективный эффект от выбора антигипертензивного препарата? Тер архив 2001; 6: 64-6.

Gertsein HC, Bosch J, Pogue J, et al. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes: the MICRO-HOPE study. Diabetes Care 1996; 19: 1225-8.

The HOPE Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.

Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-45.

Taal MW, Brenner BM. Combination ACEI and ARB therapy: additional benefit in renoprotection? Curr Opin Nephrol Hypertens 2002; 11: 377-81.

Швецов М.Ю., Медведева Т.Ю., Оконова Е.Б. и др. Блокаторы ангиотензиновых рецепторов 1 типа – новый класс нефропротективных препаратов. Клин фармакол тер 2002; 11(2): 62-9.

Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial – The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7.

McMurray JJV. Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-2 and Val-HeFT? JRAAS 2001; 2: 89-92.

Lindholm L, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertenstion study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-10.

Montalescot G, Collet JP. Preserving cardiac function in the hypertensive patient: why renal parameters hold the key. Eur Heart J 2005; 26(24): 2616-22.

Remuzzi G, Schiepatti A, Ruggenenti P. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 2002; 346: 1145-51.

Mogensen CE. The kidney in diabetes: how to control renal and related cardiovascular complications. Am J Kidney Dis 2001; 37: S2-6.

Шестакова М.В., Чугунова Л.А., Шамхалова М.Ш. и др. Диабетическая нефропатия: факторы риска быстрого прогрессирования почечной недостаточности. Тер архив 1999; 6: 38-41.

Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестник РАМН 2003; 11: 50-5.

Strutz F, Bramlage P, Paar WD. Effect of three months’ treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients. Curr Med Res Opin 2005; 21(9): 1433-40.

Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care. Curr Med Res Opin 2004; 20(10): 1625-31.

Parving H-H, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.

Keane WF, Kurokawa K, Lyle PA, et al. Treatment of type 2 diabetic patients with AT1-receptors antagonists: lessons from recent trials. Clin Exp Nephrol 2002; 6: 175-81.

Opie LH, Parving H-H. Diabetic nephropathy. Can renoprotection be extrapolated to cardiovascular protection? Circulation 2002; 106: 643-5.

Persson F, Rossing P, Hovind P, et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes 2006; 55(12): 3550-5.

Llewelyn DE, Garcia-Puig J. How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive diabetics. J Renin Angiotensin Aldosterone Syst 2004; 5(3): 141-5.

Rossing K, Christensen PK, Andersen S, et al. Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study. Diabetes Care 2003; 26(3): 569-74.

Andersen S, Brochner-Mortensen J, Parving HH; Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 2003; 26(12): 3296-302.

Komajada M. Are angiotensin II receptor blockers indicated in chronic heart failure? Heart 2002; 87: 1-2.

Беленков Ю.Н., Мареев В.Ю. Как мы лечим больных с сердечно-сосудистыми заболеваниями в реальной клинической практике. Тер архив 2003; 8: 5-11.

Palmer AJ, Rodby RA. Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria. Kidney Int Suppl 2004; (92): S118-20.

Palmer AJ, Annemans L, Roze S, et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 2004; 27(8): 1897-903.

Бойцов С.А. Изучение патогенеза гипертонической болезни продолжается. Тер архив 2005; 9: 5-12.

Rossing K, Schjoedt KJ, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68(3): 1190-8.

Мычка В.Б., Мамырбаева К.М., Масенко В.П. и др. Возможности антигипертензивной терапии ирбесартаном в коррекции инсулинорезистентности и нарушений мозгового кровотока у больных с метаболическим синдромом. Сons Med 2006; 8(11): 25-30.

Lindholm LH, Ibsen H, Borch-Jornsen K, et al. Risk of newonset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-86.

Schupp M, Pharm B, Janke J, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferators-activated receptor-? activity. Circulation 2004; 109: 2054-7.

The authors declare that there are no conflicts of interest present.